|
Liderança da Biogen Idec na Esclerose Múltipla reafirmada em Congresso nos …
RCM Pharma … “brevemente teremos a possibilidade de dispor de novos fármacos orais, nomeadamente o Fumarato de Dimetilo, a Teriflunamida e o Laquinimod, assim como de vários anticorpos monoclonais, entre eles o Daclizumab, o Ocrelizumab e o Alemtuzumab. |
 iStockAnalyst (press release) |
Abbvie, Inc: Steady Humira = Steady ABBV
iStockAnalyst (press release) Daclizumab for Relapsing Remitting Multiple Sclerosis: A Phase III candidate. Effective but well behind very good new oral options (e.g. Novartis’ Gilenya) that have similar efficacy. However, Daclizumab could be even more convenient as a once-monthly … |
Biogen Idec – Too High Too Fast?Seeking AlphaDaclizumab-HYP Phase III data readout expected in 2014. It is also for relapsing forms of MS. Biogen also filed for approval with FDA for Hemophilia Factor 8 for A and 9 for B, based on significant Phase III…
|
Research Analysts’ Ratings Reiterations for April, 29th (ABBV, BJRI, CNA, GPK …
Zolmax In the meantime, the pipeline is advancing well, with a number of meaningful data readouts expected later this year (e.g., ABT-199 at ASCO, initial Hep-C phase-3 at AASLD in November) and in 2014 (e.g., Daclizumab phase-3).” BJ’s Restaurants (NASDAQ: … |
Goldman Sachs Raises PT on Abbvie (ABBV) to $52StreetInsider.com (subscription)For example, key pipeline assets in Hep C, elagolix and daclizumab could generate over $5.5 bn at peak (exhibit 1) while we have only $3.3 bn in our total 2020 pipeline esti…
|
UPDATE: BMO Capital Raises PT on AbbVie Following 1Q13 Earnings Call
Benzinga In the meantime, the pipeline is advancing well, with a number of meaningful data readouts expected later this year (e.g., ABT-199 at ASCO, initial Hep-C phase-3 at AASLD in November) and in 2014 (e.g., Daclizumab phase-3).” AbbVie closed on Friday at … Goldman Sachs Raises PT on Abbvie (ABBV) to $52StreetInsider.com (subscription) |
|
Neue Therapien, Risikofaktoren und andere Neuigkeiten aus der Multiple …
DMSG Multiple Sklerose Nachrichten Eine einjährige Verlängerung einer Phase II Studie mit Daclizumab-HYP, einer veränderten Form des Daclizumab, zeigte dass monatliche Injektionen unter die Haut auch weiterhin die Schubhäufigkeit, die im MRT sichtbare Krankheitsaktivität und die … |
|
AbbVie’s Management Discusses Q1 2013 Results – Earnings Call Transcript
Seeking Alpha This includes Daclizumab, which is in Phase III development in partnership with Biogen, for relapsing remitting multiple sclerosis. Data from the first of two registrational trials, the select study, were recently published in the Lancet. And results … |
 La Vanguardia |
Mejora la terapia de la esclerosis múltiple – La Vanguardia
La Vanguardia A medio plazo le seguirán el daclizumab, que reduce el número de brotes en un 54%, según resultados de un estudio presentado el 4 de abril en The Lancet, y el ocrelizumab, del que hay un estudio en curso en el que Montalban es el investigador principal. |
Irish TimesBiogen Idec Management Discusses Q1 2013 Results – Earnings Call TranscriptSeeking AlphaWe expect data readouts for daclizumab in 2014, TYSABRI and SPMS in 2015 and potentially SMNrx in 2016. During that time frame, we expect to have meaning…